Deal Announcements

Solstice Bio Nets Series A Venture Capital

Monday, January 07, 2013 5:38:00 AM PDT | VentureDeal

San Francisco, California  --  Solstice Biologics (no website) has secured $18 million in its first round of venture capital investment.

Solstice is developing RNAi-based cell permeable drugs in the field of nucleic acid therapeutics.

VenBio led the round, which also included Aeris Capital AG.

The company did not disclose how the funding proceeds would be used.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin

PCI - Level1